{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:18:20Z","timestamp":1793067500497,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":367,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ymthe.2025.06.032","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T03:29:02Z","timestamp":1751426942000},"page":"4226-4238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Complement activation in a phase Ib study of fordadistrogene movaparvovec for Duchenne muscular dystrophy"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7302-1756","authenticated-orcid":false,"given":"Barry J.","family":"Byrne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell J.","family":"Butterfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry B.","family":"Shieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Licht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Binks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Casinghino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marielle","family":"Delnomdedieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kodihalli C.","family":"Ravindra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"McDonnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heliang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu P.","family":"Sirivelu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal S.","family":"Vaidya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Whiteley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel I.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.06.032_bib1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2025.06.032_bib2","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1016\/S0140-6736(19)32910-1","article-title":"Muscular dystrophies","volume":"394","author":"Mercuri","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.06.032_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175675","article-title":"Duchenne muscular dystrophy: current treatment and emerging exon skipping and gene therapy approach","volume":"947","author":"Patterson","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ymthe.2025.06.032_bib4","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: the protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.06.032_bib5","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.nmd.2014.03.008","article-title":"A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy","volume":"24","author":"Mah","year":"2014","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2025.06.032_bib6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","article-title":"The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review","volume":"12","author":"Ryder","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2025.06.032_bib7","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13023-020-01430-8","article-title":"Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis","volume":"15","author":"Crisafulli","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2025.06.032_bib8","doi-asserted-by":"crossref","first-page":"e2304","DOI":"10.1212\/WNL.0000000000012910","article-title":"Life expectancy in Duchenne muscular dystrophy: reproduced individual patient data meta-analysis","volume":"97","author":"Broomfield","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2025.06.032_bib9","first-page":"121","article-title":"Improvement of survival in Duchenne muscular dystrophy: retrospective analysis of 835 patients","volume":"31","author":"Passamano","year":"2012","journal-title":"Acta Myol."},{"key":"10.1016\/j.ymthe.2025.06.032_bib10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10654-021-00819-4","article-title":"One in five patients with Duchenne muscular dystrophy dies from other causes than cardiac or respiratory failure","volume":"37","author":"Wahlgren","year":"2022","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.ymthe.2025.06.032_bib11","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2025.06.032_bib12","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S1474-4422(22)00125-9","article-title":"Emerging therapies for Duchenne muscular dystrophy","volume":"21","author":"Markati","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2025.06.032_bib13","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymthe.2025.06.032_bib14","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/j.nmd.2022.07.251","article-title":"Phase 1\/2a trial of delandistrogene moxeparvovec in patients with DMD: 4-year update","volume":"32","author":"Mendell","year":"2022","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2025.06.032_bib15","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1212\/WNL.0000000000202973","article-title":"A phase 2 clinical trial evaluatin the safety and efficacy of delandistrogene moxeparvovec (SRP-9001) in patients with Duchenne muscular dystrophy (DMD) (S48.004)","volume":"1001","author":"Mendell","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2025.06.032_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2022.07.234","article-title":"IGNITE DMD phase I\/II study of SGT-001 microdystrophin gene therapy for DMD: longer-term outcomes and expression update","volume":"32","author":"Dreghici","year":"2022","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2025.06.032_bib17","series-title":"Presented at the Muscular Dystrophy Association Clinical & Scientific Conference, Dallas TX","article-title":"3-year outcomes update in the IGNITE DMD phase 1\/2 study of SGT-001 microdystrophin gene therapy","author":"Donisa Dreghici","year":"2023"},{"key":"10.1016\/j.ymthe.2025.06.032_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2022.07.246","article-title":"RGX-202: An investigational AAV8 gene therapy coding for a novel microdystrophin as a treatment for Duchenne muscular dystrophy","volume":"32","author":"Dastgir","year":"2022","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2025.06.032_bib19","series-title":"Presented at the Muscular Dystrophy Association Clinical & Scientific Conference, Nashville, TN","article-title":"One year data from ambulatory boys in a phase 1b, open-label study of fordadistrogene movaparvovec (PF-06939926) for Duchenne muscular dystrophy (DMD)","author":"Butterfield","year":"2022"},{"key":"10.1016\/j.ymthe.2025.06.032_bib20","article-title":"One-year data from ambulatory participants in a phase 1b study of the gene therapy fordadistrogene movaparvovec for Duchenne muscular dystrophy","author":"Butterfield","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.06.032_bib22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1517\/17425247.2014.871258","article-title":"The potential of adeno-associated viral vectors for gene delivery to muscle tissue","volume":"11","author":"Wang","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ymthe.2025.06.032_bib23","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.06.032_bib24","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1161\/01.RES.0000237661.18885.f6","article-title":"Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo","volume":"99","author":"Pacak","year":"2006","journal-title":"Circ. Res."},{"key":"10.1016\/j.ymthe.2025.06.032_bib25","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune responses to viral gene therapy vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.06.032_bib26","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173510","article-title":"Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies","volume":"134","author":"Salabarria","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.06.032_bib27","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1128\/JVI.01990-07","article-title":"Complement is an essential component of the immune response to adeno-associated virus vectors","volume":"82","author":"Zaiss","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.06.032_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.675897","article-title":"Challenges posed by immune responses to AAV vectors: addressing root causes","volume":"12","author":"Hamilton","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.06.032_bib29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/cr.2009.139","article-title":"Complement and its role in innate and adaptive immune responses","volume":"20","author":"Dunkelberger","year":"2010","journal-title":"Cell Res."},{"key":"10.1016\/j.ymthe.2025.06.032_bib30","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3389\/fimmu.2019.00337","article-title":"Complement in thrombotic microangiopathies: unraveling Ariadne's thread into the labyrinth of complement therapeutics","volume":"10","author":"Gavriilaki","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.06.032_bib31","doi-asserted-by":"crossref","first-page":"7053","DOI":"10.4081\/hr.2017.7053","article-title":"Atypical hemolytic uremic syndrome: a brief review","volume":"9","author":"Zhang","year":"2017","journal-title":"Hematol. Rep."},{"key":"10.1016\/j.ymthe.2025.06.032_bib32","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1212\/WNL.94.15_supplement.5483","article-title":"Thrombotic microangiopathy (TMA): a potential adverse reaction post Zolgensma (onasemnogene abeparvovec-xioi) therapy for spinal muscular atrophy (SMA)","volume":"94","author":"Prabhu","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2025.06.032_bib33","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","article-title":"Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series","volume":"231","author":"Chand","year":"2021","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymthe.2025.06.032_bib34","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","article-title":"Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy","volume":"6","author":"Guillou","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.06.032_bib35","first-page":"1276","article-title":"A systematic review of adeno-associated virus gene therapies in neurology: the need for consistent safety monitoring of a promising treatment","volume":"93","author":"Horton","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ymthe.2025.06.032_bib36","series-title":"Presented at the FDA + American Society of Gene + Cell Therapy (ASGT) Workshop on Immune Responses to AAV Vectos, Virtual","article-title":"Complement-activated thrombotic microangiopathy associated with AAV gene therapy","author":"Laforet","year":"2023"},{"key":"10.1016\/j.ymthe.2025.06.032_bib38","unstructured":"Belluscio, B., Beaverson, K., Garnier, N., Ryan, K. A., Moorehead, T., Yong, F., Binks, M. Safety and efficacy of PF-06939926 gene therapy in boys with Duchenne muscular dystrophy: Update on data from the Phase 1b study. Presented at the Muscular Dystrophy Association Clinical & Scientific Conference. Available at: https:\/\/www.mdaconference.org\/abstract-library\/safety-and-efficacy-of-pf-06939926-gene-therapy-in-boys-with-duchenne-muscular-dystrophy-update-on-data-from-the-phase-1b-study\/."},{"key":"10.1016\/j.ymthe.2025.06.032_bib39","first-page":"S168","article-title":"IGNITE-DMD: One-year safety and efficacy evaluation of SGT-001 microdystrophin gene therapy for Duchenne muscular dystrophy","volume":"8","author":"Shieh","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2025.06.032_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2022.107306","article-title":"Cardiac effects of 4D-310 in adults with Fabry disease in a phase 1\/2 clinical trial: Functional, quality of life, and imaging endpoints in patients with 12 months of follow up","volume":"138","author":"Schiffmann","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2025.06.032_bib44","series-title":"Presented at the New Directions in Biology and Disease of Skeletal Muscle Conference, Charleston, SC","article-title":"Complement activation in the setting of gene therapy. Experience with fordadistrogene movaparvovec in Ph1b study of boys with DMD","author":"Levy","year":"2021"},{"key":"10.1016\/j.ymthe.2025.06.032_bib45","series-title":"Presented at the Parent Project Muscular Dystrophy (PPMD), Orlando, FL","article-title":"Early, Initial data from C3391001, a first-in-human safety study of PF-06939926, a mini-dystrophin gene therapy for the potential treatment of DMD","author":"Binks","year":"2019"},{"key":"10.1016\/j.ymthe.2025.06.032_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.999021","article-title":"Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood","volume":"13","author":"Smith","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.06.032_bib47","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3233\/JND-221639","article-title":"Meeting Report: 2022 Muscular Dystrophy Association Summit on 'Safety and challenges in gene transfer therapy'","volume":"10","author":"Lek","year":"2023","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2025.06.032_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2025.06.031","article-title":"Cardiac safety of fordadistrogene movaparvovec gene therapy in Duchenne muscular dystrophy: Initial observations from a phase 1b trial","author":"Sherlock","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.06.032_bib49","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1016\/j.immuni.2024.08.007","article-title":"Antibodies and complement are key drivers of thrombosis","volume":"57","author":"Stark","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2025.06.032_bib50","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1182\/bloodadvances.2023010817","article-title":"Complement and platelets: prothrombotic cell activation requires membrane attack complex-induced release of danger signals","volume":"7","author":"Mannes","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.06.032_bib51","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood.2020007206","article-title":"Complement and the prothrombotic state","volume":"139","author":"Schmidt","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.06.032_bib52","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1089\/hum.2023.018","article-title":"Complement activation by adeno-associated virus-neutralizing antibody complexes","volume":"34","author":"West","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.06.032_bib53","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/mt.2008.76","article-title":"Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection","volume":"16","author":"Zincarelli","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.06.032_bib54","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/mt.2011.3","article-title":"A potential role of distinctively delayed blood clearance of recombinant adeno-associated virus serotype 9 in robust cardiac transduction","volume":"19","author":"Kotchey","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.06.032_bib55","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2025.06.032_bib56","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1016\/S0041-1345(03)00211-2","article-title":"Sirolimus: its discovery, biological properties, and mechanism of action","volume":"35","author":"Sehgal","year":"2003","journal-title":"Transpl. Proc."},{"key":"10.1016\/j.ymthe.2025.06.032_bib57","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/ndt\/13.1.160","article-title":"Suppression of the humoral immune response by mycophenolate mofetil","volume":"13","author":"Smith","year":"1998","journal-title":"Nephrol. Dial. Transpl."},{"key":"10.1016\/j.ymthe.2025.06.032_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2014.33","article-title":"B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study","volume":"1","author":"Corti","year":"2014","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.06.032_bib59","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1089\/humc.2015.068","article-title":"Evaluation of readministration of a recombinant adeno-associated virus vector expressing acid alpha-glucosidase in pompe disease: preclinical to clinical planning","volume":"26","author":"Corti","year":"2015","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.06.032_bib60","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.omtm.2022.07.018","article-title":"Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper","volume":"26","author":"Yang","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.06.032_bib61","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.06.032_bib63","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/jcpt.13733","article-title":"Hemophagocytic lymphohistiocytosis following gene replacement therapy in a child with type 1 spinal muscular atrophy","volume":"47","author":"Galletta","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.ymthe.2025.06.032_bib64","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMc2212912","article-title":"Dystrophin Immunity after Gene Therapy for Duchenne's Muscular Dystrophy","volume":"388","author":"Bonnemann","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.06.032_bib65","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2023.01.010","article-title":"Binding and neutralizing anti-AAV antibodies: detection and implications for rAAV-mediated gene therapy","volume":"31","author":"Schulz","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.06.032_bib66","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1681\/ASN.2015040385","article-title":"High-Throughput Genetic Testing for Thrombotic Microangiopathies and C3 Glomerulopathies","volume":"27","author":"Bu","year":"2016","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625004836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625004836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:38:22Z","timestamp":1788406702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625004836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1525001625004836"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.06.032","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complement activation in a phase Ib study of fordadistrogene movaparvovec for Duchenne muscular dystrophy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.06.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}